Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tandem Diabetes Care (TNDM) Gross Margin (2016 - 2025)

Tandem Diabetes Care's Gross Margin history spans 13 years, with the latest figure at 57.67% for Q4 2025.

  • For Q4 2025, Gross Margin rose 196.0% year-over-year to 57.67%; the TTM value through Dec 2025 reached 53.81%, up 174.0%, while the annual FY2025 figure was 53.81%, 174.0% up from the prior year.
  • Gross Margin reached 57.67% in Q4 2025 per TNDM's latest filing, up from 53.88% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 57.67% in Q4 2025 to a low of 47.41% in Q4 2023.
  • Average Gross Margin over 5 years is 51.89%, with a median of 51.86% recorded in 2022.
  • Peak YoY movement for Gross Margin: plummeted -498bps in 2023, then soared 830bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 54.16% in 2021, then dropped by -3bps to 52.39% in 2022, then decreased by -10bps to 47.41% in 2023, then increased by 18bps to 55.71% in 2024, then rose by 4bps to 57.67% in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Gross Margin are 57.67% (Q4 2025), 53.88% (Q3 2025), and 52.29% (Q2 2025).